Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Breast 1

Conditions

Leukemia, Myeloid, Acute 1Breast Neoplasms 1

Interventions

pembrolizumab 81Carboplatin 76Magnetic Resonance Spectroscopy 73Specimen Handling 69Cisplatin 62Paclitaxel 55Gemcitabine 46Fluorouracil 37Dexamethasone 37Radiation 36Docetaxel 36Cyclophosphamide 36Radiotherapy 35Pemetrexed 35Doxorubicin 35Oxaliplatin 33Leucovorin 33Bevacizumab 31Capecitabine 28Vincristine 27durvalumab 26Etoposide 24Rituximab 23Taxes 22Irinotecan 22Nivolumab 21Letrozole 21Prednisone 20Biopsy 20Platinum 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Tablets × 30 days × Clear all
NCT04055493 2026-05-11

ADAPTcycle

West German Study Group

Phase 3 Active not recruiting
1,684 enrolled
Breast

Breast Neoplasms

NCT05907057 2026-05-08

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Servier

Phase 3 Recruiting
245 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡